Request Demo

Last update 20 Mar 2025

Aloxiprin

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Aloxiprin (INN), Superpyrin

Target

COX-1 x COX-2

Action

inhibitors

Mechanism

COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Cardiovascular DiseasesSkin and Musculoskeletal Diseases

Active Indication

Joint DiseasesThrombosis

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC9H8O4.2Al.3O

InChIKeyMXCPYJZDGPQDRA-UHFFFAOYSA-N

CAS Registry9014-67-9

100 Clinical Results associated with Aloxiprin

100 Translational Medicine associated with Aloxiprin

100 Patents (Medical) associated with Aloxiprin

Literatures (Medical) associated with Aloxiprin

01 Jan 1981·European journal of rheumatology and inflammation

Once-daily piroxicam in rheumatoid arthritis: a double-blind cross-over comparison with aloxiprin.

Article

Author: Roberts, S D ; Vir, C ; Porter, K G

01 Jan 1980·Current Medical Research and OpinionQ4 · MEDICINE

Clinical experience with tolmetin sodium

Q4 · MEDICINE

Article

Author: H. W. Balme ; E. C. Huskisson ; J. A. Wojtulewski

Two studies are reported with tolmetin sodium. The first compared tolmetin sodium, phenylbutazone and placebo in rheumatoid arthritis. The second compared tolmetin sodium and aloxiprin in osteoarthritis and soft tissue rheumatism. In the first study, a double-blind crossover trial involving 12 patients, tolmetin sodium (1600 mg daily) was shown to be superior to placebo and comparable to phenylbutazone (400 mg daily). The reductions in morning stiffness and pain were statistically significant when compared to placebo. Tolmetin sodium and aloxiprin were compared in the treatment of osteoarthritis in a single-blind study which investigated efficacy and safety over a 3-month period. Initial dosages were 1600 mg tolmetin sodium and 6 g aloxiprin (equivalent to 5 g aspirin) daily. Thirty-four patients were enrolled in the study. Both drugs produced an improvement over the 3-months treatment period. The reduction in pain was statistically significant. The dosage of tolmetin sodium remained at 1600 mg daily for the 3-month duration of the study but side-effects necessitated the reduction of the dosage of aloxiprin in many patients and after 3-months' treatment the mean dosage was 4 g daily. Five patients withdrew from the tolmetin sodium group and 11 from the aloxiprin group. Adverse reactions including limiting side-effects, were about twice as common with aloxiprin compared to tolmetin sodium.

01 Aug 1978·Acta Endocrinologica

SHORT-TERM EFFECT OF ACETYLSALICYLIC ACID ANALOGUE ON PITUITARY-THYROID AXIS AND PLASMA CORTISOL LEVEL IN HEALTHY HUMAN VOLUNTEERS

Article

Author: Zavada, Milan ; Foldes, Ondrej ; Michajlovskij, N. ; Klimes, Iwar ; Jezova, Daniela ; Michalko, Jozef ; Langer, Pavel

ABSTRACTThe effect of acetylsalicylic acid analogue (aloxiprinum; Superpyrin® Spofa) administered perorally in a daily dose of 1 g per 10 kg body weight on serum levels of free thyroxine (FT4), total thyroxine (T4), triiodothyronine (T3), cortisol (F) and thyrotrophin (TSH) was studied in healthy human volunteers. In a first experiment the drug was administered for 3 days to 7 subjects, the total daily dose being divided into 4–5 aliquots, while the same total dose was administered within 4 h to another 8 subjects in a second experiment. In both experiments a highly significant increase of FT4 was found during the period of treatment, while the levels of other hormones i. e. (T3, T4, F and TSH) were decreased, in most cases significantly. After the withdrawal of the drug there was not only a return of all levels to the initial value, but in most cases an "overshoot" above this value was detected.

100 Deals associated with Aloxiprin

External Link

KEGG	Wiki	ATC	Drug Bank
D07421	Aloxiprin	B01AC15 N02BA02	DB13509

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Joint Diseases	-	-	-
Thrombosis	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis